LOX-1/OLR1 Antibody [Unconjugated] - C-terminus

CKIP-1 diminishes Oct-1-mediated LOX-1 expression. e Expression of LOX-1, CD36, and SR-A in Ckip-1−/− and Ckip-1−/−R BMDMs Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30683852), licensed under a CC-BY license. Not internally tested by R&D Systems.

CKIP-1 diminishes Oct-1-mediated LOX-1 expression. fCkip-1−/− macrophages were incubated with anti-LOX-1 antibody (10 μg per ml) or control goat IgG for 1 h prior to the addition of Dil-oxLDL or excess unlabeled oxLDL. Total uptake of Dil-oxLDL in each group was quantified. Scale bar, 25 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30683852), licensed under a CC-BY license. Not internally tested by R&D Systems.

CKIP-1 diminishes Oct-1-mediated LOX-1 expression. c Expression of LOX-1, CD36, and SR-A in WT and Ckip-1−/− BMDMs after 24 h incubation with or without 20 μg per ml oxLDL. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30683852), licensed under a CC-BY license. Not internally tested by R&D Systems.

CKIP-1 diminishes Oct-1-mediated LOX-1 expression. n Knockdown of Oct-1 expression in WT and Ckip-1−/− macrophages transfected with Oct-1-shRNA #1, #2 by lentivirus and proteins were analyzed by western blot. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30683852), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Mu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

LOX-1/OLR1 Antibody [Unconjugated] - C-terminus Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse LOX-1 (R&D Systems, Catalog # 1564-LX)
  Arg60-Ile363
  Accession # AAG44998
• Specificity: Selected for its ability to block receptor-ligand interaction in a functional ELISA assay. In Western blots, approximately 5% cross‑reactivity with recombinant human LOX-1 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: OLR1
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LOX-1/OLR1 Antibody [Unconjugated] - C-terminus

• CLEC8A
• CLEC8ASLOX1
• C-type lectin domain family 8 member A
• hLOX-1
• Lectin-like oxidized LDL receptor 1
• Lectin-like oxLDL receptor 1
• Lectin-type oxidized LDL receptor 1
• LOX1
• LOX-1
• LOX1ox LDL receptor 1
• LOXIN
• OLR1
• oxidised low density lipoprotein (lectin-like) receptor 1
• oxidized low density lipoprotein (lectin-like) receptor 1
• oxidized low-density lipoprotein receptor 1
• oxidized low-density lipoprotein receptor 1, soluble form
• Ox-LDL receptor 1
• SCARE1
• scavenger receptor class E, member 1
• SR-E1

Background

Lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1), also known as oxidized low-density-lipoprotein receptor-1 (OLR-1), is a type II transmembrane receptor belonging to the C-type lectin family (1). It also belongs to the functionally defined scavenger receptor (SR) superfamily, whose members share the common ability to bind and internalize modified forms of Low Density Lipoproteins (LDL) (2 - 4). LOX-1 is the first member of the class E scavenger receptor subfamily (SR-E). It binds and supports the internalization of multiple structurally unrelated macromolecules including oxidized LDL, advanced glycation end products (AGE), activated platelets, bacteria, apoptotic or aged cells, and heat shock proteins (5 - 7). LOX-1 has also been implicated as an intestinal receptor involved in the transcytosis of pancreatic bile salt-dependent lipase (8). The mouse LOX-1 gene encodes a 363 amino acid (aa) residue protein with a short N-terminal intracellular domain, a transmembrane domain, triple repeats of an extracellular stalk/neck region followed by a C-type lectin-like domain (CTLD) (11). The CTLD, which is required for ligand recognition, contains the six conserved cysteine residues present in all C-type lectins, but lacks the Ca²⁺-binding residues found in classical C-type lectins. LOX-1 can be detected on activated endothelial cells, vascular smooth muscle cells, macrophages, intestinal cells and dendritic cells (6 - 8). The expression of LOX-1 is induced by proinflammatory or proatherogenic stimuli, as well as by oxidized LDL itself and hemodynamic or oxidative stress. LOX-1 exists on the cell surface as covalent homodimers, which can further associate into non-covalent-linked oligomers (9). Cell surface LOX-1 can also be cleaved by yet unidentified proteases to release the soluble LOX-1 extracellular domain (6). Binding and endocytosis of oxidized LDL by LOX-1 induces oxidative stress, activates NF kappa B, and upregulates the expression of monocyte chemoattractant protein-1 and matrix metalloproteases (5 - 9). LOX-1-dependent oxidized LDL uptake also induces apoptosis by inducing the expression of the pro-apoptotic Bax and downregulation of the anti-apoptotic Bcl-2 (10). Oxidized LDL plays a key role in the pathogenesis of atherosclerosis and endothelial dysfunction. Blockade of LOX-1 functions may turn out to be a suitable target for the therapeutic intervention of atherosclerosis.

1. Sawamura, T. et al. (1997) Nature 386:73.
2. Daugherty, A. (2000) Curr. Opin. Cardiovasc. Pulm. Ren. Invest. Drugs. 2:223.
3. Platt, N. and S. Gordon (2001) J. Clin. Invest. 108:649.
4. Platt, N. and S. Gordon (1998) Chem. Biol. 5:R193.
5. Jono, T. et al. (2002) FEBS Lett. 511:170.
6. Kume, N. et al. (2001) Curr. Opin. Lipidol. 12:419.
7. Delneste, Y. et al. (2002) Immunity 17:353.
8. Bruneau, N. et al. (2003) Mol. Biol. Cell 14:2861.
9. Xie, Q. et al. (2004) DNA and Cell Biol. 23:111.
10. Chen, J. et al. (2003) Circ. Res. 94:370.
11. Hoshikawa, H. et al. (1998) Biochem. Biophys. Res. Comm. 245:841.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for LOX-1/OLR1 Antibody (AF1564)(16)

Publications using AF1564

• Borges, TJ;Lima, K;Murshid, A;Lape, IT;Zhao, Y;Rigo, MM;Lang, BJ;Siddiqui, SS;Hui, E;Riella, LV;Bonorino, C;Calderwood, SK; Innate extracellular Hsp70 inflammatory properties are mediated by the interaction of Siglec-E and LOX-1 receptors bioRxiv : the preprint server for biology 2023-12-04 [PMID: 38106019] (Neutralization, N/A)
• C Reyes, E Nova-Lampe, D Duran-Sand, D Rojas, J Gajardo, E Guzman-Gut, C Bustos-Rui, V Ormazábal, FA Zúñiga, C Escudero, C Aguayo Loxin Reduced the Inflammatory Response in the Liver and the Aortic Fatty Streak Formation in Mice Fed with a High-Fat Diet International Journal of Molecular Sciences, 2022-06-30;23(13):. 2022-06-30 [PMID: 35806336] (Western Blot, Rat)
• M Korbelik Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors Vaccines, 2021-08-14;9(8):. 2021-08-14 [PMID: 34452029] (Neutralization, Mouse)
• A Kitaura, T Nishinaka, S Hamasaki, OF Hatipoglu, H Wake, M Nishibori, S Mori, S Nakao, H Takahashi Advanced glycation end-products reduce lipopolysaccharide uptake by macrophages PLoS ONE, 2021-01-25;16(1):e0245957. 2021-01-25 [PMID: 33493233] (Neutralization, Mouse)
• Li Yan, Qingling Jia, Hui Cao, Chuan Chen, Sanli Xing, Yan Huang et al. Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX‑1 in apoE^‑/‑ mice Experimental and Therapeutic Medicine 11/9/2020 [PMID: 33262811]
• M Koga, Y Kanaoka, K Inada, S Omine, Y Kataoka, A Yamauchi Hesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages J. Pharmacol. Sci., 2020-02-28;0(0):. 2020-02-28 [PMID: 32173266] (Western Blot, Mouse)
• Torben Mentrup, Kosta Theodorou, Florencia Cabrera-Cabrera, Andreas O. Helbig, Kathrin Happ, Marion Gijbels et al. Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis Journal of Experimental Medicine 4/1/2019 [PMID: 30819724]
• Torben Mentrup, Kosta Theodorou, Florencia Cabrera-Cabrera, Andreas O. Helbig, Kathrin Happ, Marion Gijbels et al. Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis Journal of Experimental Medicine 2019-04-01 [PMID: 30819724] (Flow Cytometry, Western Blot, Mouse)
• S Hamasaki, T Kobori, Y Yamazaki, A Kitaura, A Niwa, T Nishinaka, M Nishibori, S Mori, S Nakao, H Takahashi Effects of scavenger receptors-1 class A stimulation on macrophage morphology and highly modified advanced glycation end product-protein phagocytosis Sci Rep, 2018-04-12;8(1):5901. 4/12/2018 [PMID: 29651042]
• LE Yu, CL Lai, CT Lee, JY Wang Highly electronegative low-density lipoprotein L5 evokes microglial activation and creates a neuroinflammatory stress via Toll-like receptor 4 signaling J. Neurochem., 2017-05-16;0(0):. 2017-05-16 [PMID: 28444734] (Neutralization, Mouse)
• Akamatsu T, Dai H, Mizuguchi M, Goto Y, Oka A, Itoh M LOX-1 is a novel therapeutic target in neonatal hypoxic-ischemic encephalopathy. Am J Pathol, 2014-04-13;184(6):1843-52. 2014-04-13 [PMID: 24731447] (Neutralization, Mouse)
• Ha Young Lee, Sang Doo Kim, Suk-Hwan Baek, Joon Hyuk Choi, Kyung-Hyun Cho, Brian A. Zabel et al. Serum amyloid A stimulates macrophage foam cell formation via lectin-like oxidized low-density lipoprotein receptor 1 upregulation Biochemical and Biophysical Research Communications 3/29/2013 [PMID: 23454129]
• The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int, 2012-05-23;82(7):759-70. 2012-05-23 [PMID: 22622498] (Neutralization, Mouse)
• Leptin-deficient (ob/ob) mouse ovaries show fatty degeneration, enhanced apoptosis and decreased expression of steroidogenic acute regulatory enzyme. Int J Obes (Lond), 2011-11-15;36(8):1047-53. 2011-11-15 [PMID: 22083551] (Western Blot, Mouse)
• Murshid A, Gong J, Calderwood SK Heat shock protein 90 mediates efficient antigen cross presentation through the scavenger receptor expressed by endothelial cells-I. J. Immunol., 2010-08-04;185(5):2903-17. 2010-08-04 [PMID: 20686127] (Blocking, Mouse)
• Okutsu R, Yoshikawa T, Nagasawa M, Hirose Y, Takase H, Mitani K, Okada K, Miyakoda G, Yabuuchi Y Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages. Atherosclerosis, 2008-11-17;204(2):405-11. 2008-11-17 [PMID: 19108834] (Western Blot, Mouse)

Bioinformatics

• Gene Symbol: OLR1
• Uniprot:
  • AAG44998()